paclitaxel
Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials
Lung Cancer 2022 March 29 [Link] Michael Koller, Jammbe Z Musoro, Krzysztof Tomaszewski, Corneel Coens, Madeleine T King, Mirjam A G Sprangers, Mogens Groenvold, Kim Cocks, Galina Velikova, Hans-Henning Flechtner, Andrew Bottomley Abstract Objectives: A minimally important difference (MID) is the smallest difference in quality of life (QoL) perceived as relevant by patients or clinicians.…
Read MoreLong-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival
European Journal of Surgical Oncology 2017 Janury 29 [Epub ahead of print] [Link] Sugarbaker PH, Chang D Abstract PURPOSE: Malignant peritoneal mesothelioma (MPM) is a rare disease with about 300 new cases per year in the USA. Its natural history is described as local progression within the peritoneal space in the absence of liver metastases…
Read MorePaclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells.
Biomedicine & Pharmacotherapy 2017 January [Epub ahead of print] [Link] Petrella F, Coccè V, Masia C, Milani M, Salè E, Alessandri G, Parati 4, Sisto F, Pentimalli F, Brini AT, Pessina A, Spaggiari L Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is a rare fatal asbestos-related malignancy originating in the mesothelial cells of the pleura. A…
Read MoreNanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma
Biomaterials 2016 June 22 [Epub ahead of print] [Link] Liu R, Colby AH, Gilmore D, Schulz M, Zeng J, Padera RF, Shirihai O, Grinstaff MW, Colson YL Abstract The treatment outcomes for malignant peritoneal mesothelioma are poor and associated with high co-morbidities due to suboptimal drug delivery. Thus, there is an unmet need for new…
Read MorePemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors
Investigational New Drugs. 2008 Oct 28. [Epub ahead of print] [Link] Hanauske AR, Dumez H, Piccart M, Yilmaz E, Graefe T, Gil T, Simms L, Musib L, Awada A. St. Georg Hospital, Ahrensburger Weg 129b, 22359, Hamburg, Germany, hanauskeax@lilly.com. Abstract The objectives of this phase I study were to determine the maximum tolerated dose (MTD),…
Read MorePemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
Therapeutics and Clinical Risk Management. 2008 Jun;4(3):579-85. [Link] Felip E, Rosell R. Vall d’Hebron University Hospital Barcelona, Spain. Abstract NSCLC accounts for 80% of all cases of lung cancer, which is the leading cause of cancer mortality. The majority of NSCLC patients present with advanced, unresectable disease, which remains incurable. In advanced disease, chemotherapy with…
Read MoreLong-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance
International Journal of Cancer. 2008 Jun 4. [Epub ahead of print] [Link] Barone-Adesi F, Ferrante D, Bertolotti M, Todesco A, Mirabelli D, Terracini B, Magnani C. Unit of Cancer Epidemiology, CeRMS and Center for Oncologic Prevention Piemonte, University of Turin, Turin, Italy. Abstract Models based on the multistage theory of carcinogenesis predict that the rate…
Read MoreRestrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599
Clinical Lung Cancer. 2008 Mar;9(2):102-5. [Link] Somer RA, Sherman E, Langer CJ. Department of Medical Oncology, Cooper Medical Center, Cherry Hill, NJ, USA. Abstract Background: In a previous randomized phase II trial evaluating carboplatin and paclitaxel with or without bevacizumab in patients naive to chemotherapy with advanced non-small-cell lung cancer (NSCLC), median survival ranged from…
Read MoreImpressive remission of locally advanced malignant peritoneal mesothelioma treated with combination of radiotherapy and intraperitoneal paclitaxel
European Journal of Gynaecological Oncology. 2007;28(4):322-3. [Link] Takeuchi K, Fujimoto M, Tsujino T, Takeda Y, Yoshida S. Department of Obstetrics and Gynecology, Hyogo Prefectural Tsukaguchi Hospital, Amagasaki, Japan. Abstract Background: The results of treatment of malignant peritoneal mesothelioma are quite unsatisfactory, especially in the later stages of the disease, regardless of the treatment modality employed.…
Read More